Synaf­fix ex­pands In­novent deal; Re­ci­pharm co-de­vel­ops in­halers; Vit­riVax gets $5M for vac­cine tech

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Lon­za-owned Synaf­fix boost­ed its li­cens­ing deal with In­novent Bi­o­log­ics on Wednes­day to make at least one new ADC can­di­date, build­ing up­on the com­pa­nies’ orig­i­nal deal in June 2021. In­novent will use Synaf­fix’s ADC man­u­fac­tur­ing tech­nol­o­gy to de­vel­op new ADC can­di­dates. Synaf­fix will re­ceive an up­front pay­ment as well as fur­ther mile­stone pay­ments and roy­al­ties for each com­mer­cial­ized ADC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER